Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
NeuroBo Pharmaceuticals Inc
Nieuws
NeuroBo Pharmaceuticals Inc
NRBO
NAS
: NRBO
| ISIN: US64132R1077
8/05/2024
3,930 USD
(+2,34%)
(+2,34%)
8/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
30 april 2024 ·
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
· Persbericht
17 april 2024 ·
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
· Persbericht
1 april 2024 ·
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
· Persbericht
28 maart 2024 ·
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
· Persbericht
13 maart 2024 ·
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
· Persbericht
4 maart 2024 ·
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
· Persbericht
29 februari 2024 ·
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
· Persbericht
12 februari 2024 ·
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
· Persbericht
1 februari 2024 ·
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
· Persbericht
18 januari 2024 ·
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
· Persbericht
9 januari 2024 ·
NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
· Persbericht
2 januari 2024 ·
NeuroBo to Participate in Industry and Investor Conferences in January
· Persbericht
28 december 2023 ·
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
· Persbericht
19 december 2023 ·
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
· Persbericht
1 december 2023 ·
NeuroBo to Participate in Investor Conferences in December
· Persbericht
6 november 2023 ·
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
· Persbericht
17 oktober 2023 ·
NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
· Persbericht
15 september 2023 ·
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
· Persbericht
14 augustus 2023 ·
Neurobo Pharmaceuticals Appoints Hyung Heon Kim As Chief Executive Officer And President
· Persbericht
9 augustus 2023 ·
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe